{"entity":{"id":"nct07209813","kind":"trial","name":"GKL-006 Injection Plus TACE Versus TACE Alone in Patients With Unresectable Hepatocellular Carcinoma","aka":[],"tldr":"A phase 2 trial of GKL-006 Injection in hepatocellular carcinoma, run by Beijing Gene Key Life Technology Co., Ltd, now recruiting.","summary":"GKL-006 Injection Plus TACE Versus TACE Alone in Patients With Unresectable Hepatocellular Carcinoma is a phase 2 interventional study registered as NCT07209813 by Beijing Gene Key Life Technology Co., Ltd, with 48 participants planned, started 2025-11-14 and due to reach its primary completion in 2027-09-30. Interventions recorded: GKL-006 Injection and TACE.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07209813","url":"https://clinicaltrials.gov/study/NCT07209813"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["hcc","hcc-intermediate"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["beijing-gene-key-life-technology"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07209813","phase":"2","setting":"A Multicenter, Randomized, Open-Label, Controlled Phase 2 Study of GKL-006 Injection in Combination With Transarterial Chemoembolization (TACE) Versus TACE Alone in Patients With Unresectable Hepatocellular Carcinoma","sponsor":"Beijing Gene Key Life Technology Co., Ltd","participation":[{"nct":"NCT07209813","source":"https://clinicaltrials.gov/study/NCT07209813","fetchedAt":"2026-10-07T16:55:33.599Z","studySha256":"b5eb8fd738f7ef20994d6a84a52ad42a9d16b6c7e83fb53e8d88ea7722da10f2","overallStatus":"RECRUITING","lastUpdatePosted":"2026-08-17","leadSponsor":"Beijing Gene Key Life Technology Co., Ltd","collaboratorCount":0,"minimumAge":"18 Years","maximumAge":"80 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":48,"enrolmentType":"ESTIMATED","siteCount":7,"recruitingSiteCount":7,"countries":["China"]}],"started":"2025-11-14","startedType":"actual","enrolled":48,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07209813/","neighbours":{"cancer":[{"id":"hcc","kind":"cancer","name":"Hepatocellular carcinoma","route":"/cancers/hcc/"},{"id":"hcc-intermediate","kind":"cancer","name":"Intermediate hepatocellular carcinoma (BCLC B)","route":"/cancers/hcc-intermediate/"}],"company":[{"id":"beijing-gene-key-life-technology","kind":"company","name":"Beijing Gene Key Life Technology","route":"/companies/beijing-gene-key-life-technology/"}]}}